$VSTM $1.24 with $2.40 cash per share, (37m O/S as of last 10Q, cash and cash equivalents $89m, Q/Q cash burn was ~$6M), Phase 3 data due 1H 2017 (Duvelisib - DUO , Cancer - relapsed/refractory chronic lymphocytic leukemia (CLL)), tutes had aggregated shares on 12/31/2016 of 9.49M, big gap down from $5.67 on the chart 18 months ago.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.